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ABSTRACT
Reichard, Adam. M.S. Department of Microbiology and Immunology, Wright State
University, 2012. The Effects of HSV-1 Challenge on Polarized Murine Macrophages:
An In Vitro Model Using the J774A.1 Murine Macrophage Cell Line.
In our current study we examined the effects of HSV-1 challenge on J774A.1
macrophages polarized to either a proinflammatory (M1) or anti-inflammatory (M2)
phenotype. Polarized J774A.1 macrophages were characterized using CD14-CD86 and
SOCS1-SOCS3 expression levels. SOCS proteins are a family of proteins that are
capable of inhibiting cytokine-signaling pathways. HSV-1 up regulates expression of
SOCS1 protein levels in infected cells, inhibiting the ability of infected cells to produce
proinflammatory products (Nowoslawski Akhtar and Benveniste, 2011). This study
shows that signals within the microenvironment play a greater role in macrophage
polarization, and SOCS1-SOCS3 expression levels, than does HSV-1 challenge. M1
macrophages showed morphological changes following polarization, a significant
decrease in cell viability, a two-fold increase in the number of CD14+-CD86+ cells,
similar levels of SOCS1 expression, and a 11-fold decrease in SOCS3 expression when
compared to control cells. M2 macrophages also exhibited morphological changes, a
slight decrease in cell viability, a 26.0% decrease in the number of CD14+-CD86+ cells,
and SOCS1-SOCS3 expression levels similar to that of control cells. Following HSV-1
challenge (0.1 MOI), the majority of M1 macrophages and M2 macrophages appeared
rounded, possibly due to disruption of actin filaments. Virus-infected M1 macrophages
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showed a slight decrease in cell viability when compared to uninfected M1 macrophages.
Additionally, the number of CD14+-CD86+ cells of both M1 and M2 phenotypes
decreased. M1 macrophages exhibited a 39.9% decrease, while M2 macrophages
exhibited a 13.2% decrease. SOCS1 expression levels remained relatively unchanged in
virus-infected M1 macrophages, while SOCS3 expression levels increased by 30.4% at
24 hours after infection. Increase in SOCS3 levels is hypothesized to be a protective
response of infected M1 macrophages due to the release of high levels of
proinflammatory molecules. Alternatively, the SOCS1-SOCS3 ratio remained relatively
unchanged in the anti-inflammatory phenotype.
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Introduction

Herpes simplex virus type-1 (HSV-1) is a dsDNA virus that currently affects
approximately 70-80% of adults within the United States (Roizman et al., 2007; Dakvist
et al., 1995; Miller et al., 1998; Stock et al., 2001). Under normal conditions, a latent
infection is established and maintained within the host. If the host immune system is
compromised, the virus can be reactivated, resulting in a lytic infection (Cunningham et
al., 2006; Diefenbach et al., 2008; Koelle and Corey, 2008; Roizman et al., 2007). Lytic
infections clinically manifest as mild cutaneous disease. At a lesser frequency HSV-1
reactivation can result in infection of the corneal epithelium and possibly lead to
blindness (Cheng et al., 2000).
The host immune response to HSV-1 infection is very complex and involves cells
of both the innate and adaptive immune system. The innate immune response to HSV-1
infection is comprised of three main cell types: natural killer cells (NK), macrophages,
and γ/δ T cells. These cells are recruited to the site of infection and activated when
infected keratinocytes release high levels of cytokines. This release of cytokines activates
innate immune cells that attempt to control the infection by killing infected cells and
inhibiting virus replication (Cunningham et al., 2006; Mikloska et al., 1998). Even
though the microenvironment during HSV-1 infection is incredibly complex, it is well
established that macrophages play a pivotal role in controlling HSV-1 replication.
Macrophages are capable of inhibiting virus replication within themselves when infected.
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Additionally, macrophages can inhibit the viral activity of extracellular particles, and
possess the ability to target and destroy virus-infected cells, slowing virus replication in
infected neighboring cells (Wu and Morahan, 1992). In this study the J774A.1 murine
macrophage cell line was selected due to the important role macrophages play in
controlling HSV-1 infections.
Macrophages are considered "professional" phagocytic cells, meaning, they
express a wide variety of cell surface receptors allowing them to recognize signals not
normally found within the host. Signals present within the microenvironment can alter
macrophage function and lead to multiple effector subpopulations (Murray and Wynn,
2011). This ability to alter function is known as macrophage "polarization". The two
polarized macrophage populations we examined in this study are known as M1 and M2
macrophages; however, there are multiple M2 like subtypes that are currently known. M1
macrophages are a proinflammatory, "classically" activated, population that secrete high
amounts of proinflammatory cytokines, such as inducible nitric oxide synthases (iNOS)
and tumor necrosis factor-α (TNF-α), following activation by interferon-gamma (IFN-γ)
and lipopolysaccharide (LPS). M2 macrophages are activated by interleukin-4 (IL-4) or
interleukin-13 (IL-13), and are considered anti-inflammatory due to the molecules they
release, such as interleukin-10 (IL-10), that lead to tissue remodeling and angiogenesis
(Junliang et al., 2010; Kigerl et al., 2009; Wang et al., 2010).
In our preliminary studies we found that polarization treatment leads to
morphological changes. Following IFN-γ and LPS treatment, M1 macrophages appeared
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flattened, were irregularly shaped, and contained many visible intracellular vacuoles. M1
treatment also led to a decrease in cell viability, possibly due to IFN-γ/TNF-α toxicity
(Kyoungho et al., 2001). M2 treatment induced cells with an elongated morphology,
similar to that seen in control macrophages cultures in the majority of cells following IL4 treatment. Untreated control macrophages appeared as round or elongated in culture.
In order to identify accurately the M1 and M2 phenotype following treatment, it
was necessary to characterize markers that accurately discriminated between the two
phenotypes. Cluster of differentiation marker 14 (CD14) and cluster of differentiation 86
(CD86) were expressed at different levels in the two phenotypes, making CD14 and
CD86 effective markers for identification of the M1 and M2 subpopulations. M1
macrophages showed a significantly higher number of CD14+-CD86+ cells when
compared to control cells, while M2 macrophages showed a significant decrease in the
number of CD14+-CD86+ cells.
Suppressor of cytokine signaling (SOCS) proteins are frequently manipulated by
viruses to maintain an infection within the host (Nowoslawski Akhtar and Benveniste,
2011). The function of the different SOCS proteins is to inhibit the cytokine-signaling
pathway, thereby influencing the inflammatory response (Nowoslawski Akhtar and
Benveniste, 2011). SOCS proteins can be quickly up regulated in macrophages, making
SOCS protein expression levels a target of observation in our study (Whyte et al., 2011).
Our goal was to determine the effects HSV-1 challenge plays on morphology, CD14CD86 expression, cell viability, and SOCS protein levels in M1 and M2 macrophages.
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Hypothesis: The cytokines/signals present within the microenvironment play a
greater role in macrophage polarization, than infection with HSV-1.
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Literature Background and Preliminary Observations

HSV-1
Herpes simplex virus is a dsDNA virus that undergoes replication within the cell
nucleus of the host (Roizman et al., 2007). HSV-1 infections are found throughout the
world, and under normal circumstances, only infect humans (Whitley and Roizman,
2001). It is estimated that HSV-1 affects approximately 70-80% of adults (Dakvist et al.,
1995; Miller et al., 1998; Stock et al., 2001), the virus remains latent until reactivation
leads to cutaneous or mucocutaneous disease, which is most often mild (Arduino and
Porter, 2006). At a lesser frequency HSV-1 can infect the cornea resulting in corneal
scarring, and when high infectious doses are used, can lead to fatal encephalopathy in
mice (Cheng et al., 2000).
HSV-1 gains entry into cells of the mucosal membrane by attaching to the cell
surface by way of glycoproteins gB, gC, gD, gH, and gL. Two additional glycoproteins,
gE and gI, facilitate HSV-1 infection of neighboring cells (Rajcani et al., 2000).
Following infection of the mucosal membrane, sensory nerve fibers retrogradely
transport virus to the neuronal cell body of the trigeminal, or dorsal root ganglion where a
latent infection is established and maintained. The virus can periodically reactivate and
anterogradely travel to the original site of infection, leading to cutaneous disease
(Cunningham et al., 2006; Diefenbach et al., 2008; Koelle and Corey, 2008; Roizman et
al., 2007).
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The microenvironment during HSV-1 infections involves many cell types that are
part of a complex immune response to control virus replication and destroy infected cells.
Upon infection keratinocytes secrete large amounts of cytokines that lead to the
recruitment and activation of NK cells, macrophages, and γ/δ T cells (Cunningham et al.,
2006; Mikloska et al., 1998).
Even though the microenvironment influences many cell types, macrophages play
a pivotal role in controlling virus replication during HSV-1 infections (Staats et al., 1991;
Johnson, 1964). One possible mechanism is the ability of a macrophage to inhibit virus
replication within itself, and the second mechanism involves the ability of a macrophage
to inhibit the activity of extracellular virus particles, destroy virus-infected cells, and slow
virus replication in infected neighboring cells (Wu and Morahan, 1992). In the present
study the J774A.1 murine macrophage cell line was selected due to the vital role
macrophages play during HSV-1 infection.

Macrophage Function and Polarization
Haematopoietic stem cells, which are located in bone marrow, differentiate into
monocytes and are released into circulation. Monocytes differentiate to macrophages and
dendritic cells (DC) once they pass through the endothelium and take up residence within
tissues. Therefore, the main role of monocytes is to replenish macrophages and DCs that
reside in tissue. Macrophages are "professional" phagocytic cells that express a wide
variety of surface receptors recognizing signals that are not normally expressed by tissues
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within the host, making them a vital component of the host immune system.
Macrophages are widely distributed within the body and alter their function depending on
signals present in the microenvironment (Murray and Wynn, 2011). This ability to
differentiate into different macrophage subpopulations is known as macrophage
"polarization".
Macrophages exist as multiple subpopulations within the host, and depending on
which signals are present, can respond in either a proinflammatory or anti-inflammatory
manner. When treated with IFN-γ and LPS, macrophages respond by producing
proinflammatory molecules such as iNOS and TNF-α, and are termed M1 macrophages
(Junliang et al., 2010; Kigerl et al., 2009; Wang et al., 2010). Preliminary experiments
with IFN-γ/LPS in this study showed that M1 macrophages exhibited morphological
differences when compared to control cells. The M1 macrophage response is necessary to
control virus replication, however, a consequence of inflammation is host tissue damage.
In regards to corneal HSV-1 infections, inflammation is responsible for corneal scarring
and can lead to blindness.
When macrophages are treated with IL-4 or IL-13, they respond by releasing antiinflammatory molecules that lead to tissue remodeling and angiogenesis. These antiinflammatory macrophages are known as the M2 macrophage subpopulation (Junliang et
al., 2010; Kigerl et al., 2009; Wang et al., 2010). Additional types of M2-like
macrophages exist. Ligation of the TGF-ß receptor, IL-10 receptor, or FC gamma
receptors in the presence of LPS, has been shown to lead to multiple M2 like
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subpopulations (Martinez et al., 2008; Gordan and Martinez, 2010; Mosser and Edwards,
2008). The balance between proinflammatory and anti-inflammatory macrophage
populations is important clinically because different macrophage subtypes have been
shown to exacerbate certain disease processes (Junliang et al., 2010; Cheng et al., 2000).

Cluster of Differentiation Markers
In our study it was necessary to establish markers that differentiated between the
M1 and M2 subtypes. In order to do this we looked at differences in expression levels of
two specific cell surface receptors found on macrophages, cluster of differentiation 14
(CD14) and cluster of differentiation 86 (CD86). CD14 has been shown to form a
receptor complex with TLR4; this receptor complex binds LPS with high affinity,
resulting in a signaling cascade and the activation of multiple transcription factors
(Dobrovolskaia and Vogel, 2002). CD86 (B7-2) is a co-stimulatory molecule found on
the surface of antigen presenting cells. Co-stimulation of naive T cells with CD86 leads
to T cell activation and survival (Sugamura et al., 2004).

Cell Viability
Cell viability experiments showed that there was a decrease in the number of
viable cells following M1 treatment. Since M1 macrophages secrete high levels of TNF-α
(Junliang et al., 2010; Kigerl et al., 2009; Wang et al., 2010); this decrease in cell
viability was attributed to potential IFN-γ/TNF-α toxicity. Kyoungho et al. (2001), found
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that IFN-γ and TNF-α together led to death of pancreatic islet cells through activation of
the classical caspase-dependent apoptotic pathway. However, IFN-γ or TNF-α alone did
not lead to apoptosis, implying both are required for toxicity. In order to prove that the
presence of IFN-γ and TNF-α in culture led to a decrease in cell viability, anti-TNF-α
neutralizing antibodies were added to M1 cell cultures to protect cells from the toxic
effects of IFN-γ and TNF-α. Only minimal protection occurred in these 24-hour cultures.
Since the action of anti-TNF-α antibodies takes place slowly (18-24 hours), further
exploration of this decrease in cell viability is necessary.

SOCS Proteins
Suppressor of cytokine signaling (SOCS) proteins have been shown to be a
frequent target for viral manipulation (Nowoslawski Akhtar and Benveniste, 2011). Eight
members of the SOCS protein family have been identified; all of them can be rapidly
expressed in macrophages (Whyte et al., 2011). The main function of SOCS proteins is to
limit the inflammatory response while still maintaining a sufficient immune response to
clear pathogens. Therefore, regulation of SOCS proteins is crucial in ensuring the
immune response is sufficient enough to clear pathogens, while avoiding excessive host
tissue damage. SOCS1 and SOCS3 possess a kinase inhibitory region (KIR), the main
function of which is to inhibit kinase activity, and ultimately inhibit signaling thorough
the JAK/STAT pathway (Nowoslawski Akhtar and Benveniste, 2011).
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Materials and Methods

Cell Lines
The J774A.1 murine macrophage cell line (ATCC) is a reticulum cell sarcoma, adherent
macrophage cell line derived from an adult female BALB/cN mouse. J774A.1 cells were
propagated in 25 cm2 vented cap cell culture flasks and incubated at 37°C and 5% CO2
using a water-jacketed incubator. Cells were cultured in a medium consisting of
Dulbecco's Modified Eagle's Medium (DMEM) containing 10% heat inactivated fetal
bovine calf serum (FCS). Cells were subcultured at a subcultivation ratio of 1:6, two to
three times weekly. Cell culture flasks, growth medium, and fetal bovine calf serum were
purchased from Fisher Scientific.

Polarization Treatment
J774A.1 macrophages were grown to approximately 50% confluency, at which time the
polarization treatment was administered. To induce the M1 phenotype J774A.1
macrophages were treated with IFN-γ (20 ng/mL) and LPS (100 ng/mL) for 24 hours; IL4 (20 ng/mL) was used to induce the M2 phenotype. After 24 hours cells were removed
from the cell culture flasks using a cell scraper so they could be further analyzed. The
murine cytokines (IFN-γ and IL-4) were purchased from Peprotech; LPS was purchased
from Chondrex.
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Cell Viability
J774A.1 macrophages were grown to approximately 50% confluency, at which time
either IFN-γ/LPS (M1) or IL-4 (M2) were added with or without virus. Untreated cells
were used as a control. After 24 hours cells were removed from the cell culture flasks
using a cell scraper. Cells were then centrifuged at 4˚C for 5 minutes to obtain a cell
pellet. The supernatant was aspirated following centrifugation and the cell pellet was
resuspended in 1 mL of complete growth medium. Trypan blue (Fisher Scientific) was
used to determine viability, and a hemocytometer was used to obtain cell counts.

TNF-α Neutralization
Protocol 1: J774A.1 macrophages were grown to approximately 50% confluency, at
which time IFN-γ and LPS were added for 24 hours simultaneously with anti-TNF-α
neutralizing antibodies. After 24 hours cells were removed using a cell scraper and
centrifuged at 4˚C for 5 minutes to obtain a cell pellet. The supernatant was aspirated and
1 mL of complete growth medium was used to resuspend the cell pellet. Trypan blue was
used to determine viability and a hemocytometer was used to obtain counts of visible
cells.

Protocol 2: J774A.1 macrophages were grown to approximately 50% confluency, at
which time IFN-γ and LPS was added for 24 hours. After 24 hours the supernatant was
collected and separated into two 15 mL centrifuge tubes. Anti-TNF-α neutralizing
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antibodies were added to one of the 15 mL centrifuge tubes, both 15 mL centrifuge tubes
were then placed in the incubator (37°C and 5% CO2) for 24 hours. After 24 hours the
supernatant was added to untreated cells for an additional 24 hours, after which time the
cells were collected using a cell scraper. Cells were then centrifuged at 4˚C for 5 minutes
in order to obtain a cell pellet. After centrifugation the supernatant was aspirated and the
cell pellet was resuspended using 1 mL of complete growth medium. Trypan blue was
used to determine cell viability and a hemocytometer was used to obtain counts of viable
cells.

Immunofluorescent Staining
Cells were grown in slide chambers (Fisher Scientific) to approximately 50% confluency,
at which time either IFN-γ and LPS (M1) or IL-4 (M2) were added for 24 hours with and
without virus. Untreated cells were used as an experimental control. Following
polarization treatment, cells were rinsed with 1% bovine serum albumin (BSA)
suspended in phosphate buffered saline (PBS). Cells were then fixed using 4%
Paraformaldehyde/PBS (15 minutes at room temperature) and permeabilized using icecold acetone (10 minutes at -20˚C). Blocking buffer (5% serum from species of
fluorochrome-conjugated primary antibody or fluorochrome-conjugated secondary
antibody, 3% BSA, suspended in PBS) was added for 1 hour at room temperature.
Following blocking, antibodies were diluted in blocking buffer and added per
recommended concentration from distributor. Slide chambers were then incubated
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overnight at 4˚C. For fluorochrome-conjugated primary antibodies (CD14, CD86) and
Phalloidin, cells were rinsed following incubation and a cover slip was added using
VectaShield hard set mounting medium (VectaShield from Vector Laboratories). For
primary antibodies not fluorochrome-conjugated (SOCS1 and SOCS3), cells were rinsed
following incubation, at which time a fluorochrome-conjugated secondary antibody was
added for 1 hour (1:50 dilution) at room temperature. A coverslip was then added using
VectaShield hard set mounting medium. Fluorescence microscopy was used to analyze
slides. Anti-CD14 and anti-CD86 antibodies were purchased from BioLegend; antiSOCS1 and anti-SOCS3 antibodies were a gift from Dr. Howard Johnson (University of
Florida); FITC-conjugated secondary antibody was purchased from Invitrogen; Texas
Red-Phalloidin X was purchased from Life Technologies. *Between each step cells were
rinsed three times for three minutes using 1% BSA/PBS.

Antibody/Stain

Concentration/Dilution

FITC anti-mouse CD14

0.25 µg/million cells

Brilliant Violet 421 anti-mouse CD86

5 µL/million cells

Texas Red-Phalloidin X

5 µL/million cells

anti-mouse SOCS1 (rabbit) and anti-mouse

10 µg/million cells

SOCS3 (rabbit)
FITC anti-rabbit secondary (goat)
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Flow Cytometry
Cells were grown to approximately 50% confluency in cell culture flasks, at which point
M1 or M2 treatment was administered with or without virus. After 24 hours of treatment,
cells were removed using a cell scraper and centrifuged at 4˚C for 5 minutes in order to
obtain a cell pellet. After centrifugation the supernatant was aspirated and the cell pellet
was resuspended using 1 mL of complete growth medium. A hemocytomter was used to
obtain viable cell counts; one million cells were used for each sample.
Cell surface staining (CD14 and CD86): Cells were rinsed three times with 1%
BSA/PBS. For cell surface markers no permeabilization step was required. Blocking
buffer (5% mouse serum/3% BSA/PBS) was added to cells for 45 minutes at room
temperature. Following blocking, antibodies were diluted in blocking buffer and added to
cells per concentrations suggested by distributor for 45 minutes at 4˚C. After antibody
incubation, cells were fixed using 4% Paraformaldehyde/PBS for 15 minutes at room
temperature. Cells were then rinsed three times and resuspended in 250 µL of ice cold
PBS with 0.5% sodium azide. Samples were then analyzed using an Accuri C6 flow
cytometer.

Intracellular staining (SOCS1 and SOCS3): Cells were rinsed three times with 1%
BSA/PBS. After rinsing cells were fixed with 4% Paraformaldehyde/PBS for 15 minutes
at room temperature. Cells were then rinsed three times. Next, cells were permeabilized
using 0.2% Triton-X/PBS for 15 minutes at room temperature. Cells were then rinsed
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three times. Blocking buffer (5% goat serum/3% BSA/PBS) was added to cells for 1 hour
at room temperature. Following blocking, SOCS1 and SOCS3 antibodies were suspended
in blocking buffer at a concentration of 10 µg/million cells and added to cells for 45
minutes at 4˚C. Cells were then rinsed three times. After rinsing, FITC-conjugated
secondary antibody was diluted in blocking buffer (1:50 dilution) and added to cells for
45 minutes at 4˚C. Cells were then rinsed three times and suspended in ice cold PBS with
0.5% sodium azide. Samples were analyzed using an Accuri C6 flow cytometer.

Antibody

Concentration/Dilution

FITC anti-mouse CD14

0.25 µg/million cells

PE/Cy5 anti-mouse CD86

0.25 µg/million cells

anti-mouse SOCS1 (rabbit) and anti-mouse

10 µg/million cells

SOCS3 (rabbit)
FITC anti-rabbit secondary (goat)

1:50

Virus Challenge
Cells were grown to approximately 50% confluency in cell culture flasks. Cells were then
removed using a cell scraper and centrifuged at 1500 revolutions per minute (4˚C) for 5
minutes. After centrifugation the supernatant was aspirated and the cell pellet was
resuspended using 1 mL of complete growth medium. Packed cell volume (PCV) cell
counting tubes (MidSci) were used to obtain cells counts so multiplicity of infection
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(MOI) could be accurately calculated. Cells were added to cell culture flasks; M1 and M2
treatments were then administered simultaneously with 0.1 MOI of HSV-1. After 24
hours cells were collected so they could be further analyzed.

Statistical Significance
Statistical significance was calculated using a paired t-test (SigmaPlot 12.0); all
experiments were completed at least twice.
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Results

Polarized Macrophages Exhibited Morphological Changes When Compared to
Control Macrophages
Following treatment with IFN-γ and LPS for 24 hours, M1 macrophages appeared
flattened, were irregularly shaped, and contained visible intracellular vacuoles (Fig. 1).
The M2 phenotype exhibited an elongated cellular morphology following treatment with
IL-4 (Fig. 1) when compared to control cells, which included cells with both a rounded
and elongated morphology (Fig.1). The morphological changes exhibited by M1 and M2
macrophages made it possible to differentiate between the two phenotypes based on
morphology alone.

CD86 is Up Regulated in Uninfected M1 Macrophages and Down Regulated in
Uninfected M2 Macrophages
CD86 is up regulated in macrophages treated with IFN-γ and LPS, making it an
accurate identifier of the M1 phenotype (Fig. 2, Fig. 5, and Fig. 6) when used in
conjunction with CD14 expression. Additionally, CD14-CD86 is down regulated
following IL-4 treatment, allowing for identification of the M2 phenotype (Fig. 3, Fig. 5,
and Fig. 6) (Kigerl et al., 2009). Therefore, an increase in the number of CD14+-CD86+
cells was used to identify the M1 phenotype, while a decrease in the number of CD14+-
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CD86+ cells was used to identify the M2 phenotype. Untreated cells were used as an
experimental control for CD14+-CD86+ expression (Fig. 4, Fig. 5, and Fig. 6).

Uninfected M1 Macrophages Exhibited a Decrease in Cell Viability Following
Treatment with IFN-γ and LPS for 24 Hours
Cell viability experiments showed a decrease in the number of viable cells
following treatment with IFN-γ and LPS for 24 hours (Fig. 7). M1 macrophages showed
a 31.0% decrease in the number of viable cells when compared to control cells. M2
macrophages exhibited on a 9.0% decrease, following IL-4 treatment for 24 hours, when
compared to control cells. The decrease in M1 macrophage cell viability is due to
potential toxicity from secreted pro-inflammatory products.

M1 Macrophages Showed High Expression Levels of SOCS1 in Comparison to
SOCS3, while Both M2 and Control Macrophages Expressed Higher Levels of
SOCS3 in Comparison to SOCS1
Following polarization, M1 macrophages expressed higher levels of SOCS1 when
compared to SOCS3, resulting in a 6.1:1 SOCS1-SOCS3 ratio (Fig. 8, Fig. 11, and Fig.
14), while M2 macrophages expressed more SOCS3 than SOCS1 resulting in a SOCS1SOCS3 ratio of 1:2.2 (Fig. 9, Fig. 12, and Fig. 14). Control macrophages expressed
SOCS proteins similarly to that of M2 macrophages with a SOCS1-SOCS3 ratio of 1:1.9
(Fig. 10, Fig. 13, and Fig. 14).
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Virus Challenge Leads to Morphological Changes in Polarized and Control
Macrophages
Uninfected control macrophages included both round and elongated cells.
Uninfected M1 macrophages were flattened, irregularly shaped, and contained visible
intracellular vacuoles, while M2 macrophages exhibited an elongated morphology.
Following challenge with 0.1 MOI of HSV-1, M1 macrophages appeared rounded (Fig.
15). Similar morphological changes were observed in M2 macrophages and control
macrophages when virus was introduced to cultures (Fig.15). Therefore we concluded
that viral challenge leads to a rounded morphology in virus-infected polarized and control
macrophages. Consequently, virus induced morphological changes made it difficult to
differentiate between phenotypes based on morphology alone.

HSV-1 Infection Decreases Expression of CD14 and CD86 in M1, M2, and Control
Macrophages
CD 14 and CD 86 were expressed by both M1 and M2 macrophages, but at
varying levels, allowing both CD14 and CD86 to be used as markers to discriminate
between the two phenotypes. Before virus challenge, M1 macrophages showed an
increase (41.2%) in the number of CD14+-CD86+ cells when compared to control cells.
Conversely, M2 macrophages exhibited a decrease (26.9%) in the number of CD14+CD86+ cells. This allowed us to correlate an increase in CD14+-CD86+ expression to the
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M1 phenotype and a decrease to the M2 phenotype. Following challenge with 0.1 MOI of
HSV-1, overall expression of CD14 and CD86 was decreased. Immunofluorescent
images of virus-infected M1 macrophages stained with anti-CD86 antibodies showed an
increase in CD86 expression in comparison to virus-infected control cells (Fig. 16 and
Fig. 18). M2 macrophages stained with anti-CD86 antibodies did not show any
observable differences when compared to virus-infected control cells (Fig. 17 and Fig.
18). Flow cytometric analysis of virus-infected M1 macrophages showed an increase in
the number of CD14+-CD86+ cells when compared to virus-infected control cells (Fig. 19
and Fig. 20), while the M2 phenotype showed a decrease (Fig.19 and Fig. 20). When
compared to their uninfected counterparts, CD14-CD86 expression in virus-infected M1,
M2, and control cells was decreased. Virus-infected M1 macrophages showed a 39.4%
decrease (p-value=0.001) and virus-infected M2 macrophages showed a decrease of
13.2% (p-value=0.039) (Fig. 21). Virus-infected control macrophages also showed a
significant decrease of 27.8% (p-value=0.022) (Fig.21). These results suggest that HSV-1
infection decreases the ability of polarized and control macrophages to express both
CD14 and CD86. While CD14 and CD86 may not play a direct role in the innate immune
response to HSV-1 infection, CD14-CD86 expression is an indicator of a macrophages
ability to mount an effective proinflammatory immune response. CD86 is an important
surface molecule that stimulates naive T cells and leads to their maturation and
activation. T cells play an important role in the adaptive immune response to HSV-1
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infection, signifying the importance of CD86 expression levels on the surface of
macrophages found at the infection site.

Following IFN-γ and LPS, Virus-Infected Macrophages Experience a Significant
Decrease in Cell Viability
Following IFN-γ and LPS treatment, virus-infected M1 macrophages exhibited a
decrease in the number of viable cells when compared to virus-infected control cells (Fig.
22). This decrease in cell viability may be due to potential IFN-γ/TNF-α toxicity. In order
to demonstrate this we added anti-TNF-α neutralizing antibodies to culture at the same
time point as M1 polarization treatment and virus treatment. However, only a slight,
statistically insignificant, increase resulted. It is well documented that M1 macrophages
secrete high levels of TNF-α. In our study we found that M1 polarization can occur as
quickly as 12 hours, leading to TNF-α production. The anti-TNF-α neutralizing
antibodies require 24 hours to effectively neutralize TNF-α. This time frame does not
allow the neutralizing antibody enough time to neutralize newly synthesized TNF-α,
rendering the anti-TNF-α neutralizing antibody ineffective. Therefore, more work needs
to be completed. Nevertheless, there was a statistically significant decrease in viability in
virus-infected M1 macrophages when compared to virus-infected control cells by an
unknown mechanism.
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Virus Challenge Up Regulates SOCS3 Expression in M1 Macrophages, and SOCS1
Expression in Control Cells
Immunofluorescent images showed that virus-infected M1 macrophages
expressed comparable levels of SOCS1 and SOCS3, while virus-infected M2
macrophages expressed higher levels of SOCS3 compared to SOCS1 (Fig. 23 and Fig.
24). Virus-infected control cells showed an increase in SOCS1 expression compared to
uninfected control cells, while SOCS3 was decreased in control cells following virus
infection (Fig. 25). Flow cytometric analysis of virus-infected M1 macrophages
suggested that virus challenge leads to up regulation of SOCS3 (Fig. 26). Following virus
challenge, M1 macrophages exhibited a SOCS1-SOCS3 ratio of 1:1.1, compared to a
SOCS1-SOCS3 ratio of 6.1:1 in uninfected M1 macrophages (Fig. 29 and Table 1).
These data suggest the microenvironment signals that lead to M1 polarization, play a
greater role in polarization and activation of the M1 subset than does challenge with
HSV-1. SOCS expression levels appeared relatively unchanged in virus-infected M2
macrophages when compared to uninfected M2 macrophages (Fig. 27). Both samples
expressed significantly higher levels of SOCS3 compared to SOCS1. Virus-infected M2
macrophages exhibited a SOCS1-SOCS3 ratio of 1:1.8, while uninfected M2
macrophages cells exhibited a ratio of 1:2.2, once again signifying the importance of
microenvironment signals (Fig. 29 and Table 1). Virus-infected control cells showed high
expression levels of SOCS1 when compared to SOCS3 (Fig.28). By contrast, the SOCS1-
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SOCS3 ratio in virus-infected control cells was 3.8:1, while uninfected control cells
exhibited a ratio of 1:1.9 (Fig.29 and Table 1).
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Discussion

In this study J774A.1 macrophages were polarized to either the M1 or M2
phenotype. M1 macrophages were flattened, irregularly shaped, and contained visible
intracellular vacuoles. Uninfected M1 macrophages were more adherent when compared
to uninfected M2 and uninfected control macrophages. Uninfected M2 macrophages
developed into elongated cells, which more closely resembled uninfected control cells,
which included both elongated and rounded cells. Following challenge with virus, the
majority of cells in M1, M2, and control cultures were rounded, making it difficult to
differentiate based on morphology. These data suggest virus infection leads to a rounded
morphology in polarized and control cells, making it difficult to identify the M1 and M2
phenotypes based on morphology. This rounded morphology is possibly due to disruption
of the actin cytoskeleton. HSV-1 infection leads to actin cytoskeleton disruption.
Disruption of the actin cytoskeleton is required for the HSV-1 to replicate effectively
(Ying et al., 2010).
Following M1 treatment, a significant decrease in cell viability occurred, this was
not observed following M2 treatment. The decrease in M1 cell viability may stem from
TNF-α production. It has been documented that the combination of IFN-γ and TNF-α in
culture is toxic to cells (Kyoungho et al., 2001). This would explain why IFN- γ treated
cells secreting TNF-α, would have a decrease in viability. M1 macrophages may
continuously secrete TNF-α while being stimulated with IFN-γ and LPS, not allowing
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enough time for the neutralizing antibodies to bind and inhibit function of newly
synthesized TNF-α in culture. Additionally, the effectiveness of anti-TNF-α neutralizing
antibodies relies on TNF-α not being degraded within the 24-hour time point.
CD14 and CD86 expression were used as markers to identify the M1 and M2
phenotype. Using immunofluorescent imaging and flow cytometric analysis, a significant
increase in the number of cells expressing both CD14 and CD86 was observed, while M2
macrophages showed a significant decrease in expression of both molecules. However,
following viral challenge, there was an overall decrease in CD14 and CD86 expression in
all three experimental groups. Therefore, HSV-1 infection decreases the ability of M1,
M2, and control cells to express both CD14 and CD86. This decrease made it difficult to
identify M1 and M2 phenotypes based on the criteria set before virus infection. However,
while viral challenge led to an overall decrease in CD14 and CD 86 expression, the trend
was maintained. Virus-infected M1 macrophages still showed an increase in CD14-CD86
expression when compared to virus-infected control cells; similar to what was seen in
uninfected M1 macrophages. Additionally, M2 macrophages showed a decrease in
CD14-CD86 expression when not treated, or treated, with HSV-1. It appears the signals
within the microenvironment play a key role in CD14-CD86 expression, and HSV-1
infection decreases total expression.
The unpolarized control macrophage may represent the initial subtype of the
macrophage lineage present at the HSV-1 infection site. Note that SOCS1 expression
levels increased from 30.5% to 83.7% at 24 hours after HSV-1 infection. There was also
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a decrease in SOCS3 expression levels from 57.7% to 22.1%. The increase in SOCS1
expression levels inhibits the ability of this macrophage subtype to produce proinflammatory products through disruption of the JAK-STAT signaling pathway, while
the decrease in SOCS3 expression suggests that SOCS3 may have been compromised
following HSV-1 infection. Once polarized to the M1 phenotype, the macrophages were
resistant to the increase in SOCS1, however, there was an increase in SOCS3 expression
levels. This increase in SOCS3 expression could be a protective mechanism to protect the
cells from pro-inflammatory secretory products. There was essentially no difference in
SOCS1 and SOCS3 expression levels in virus-infected and uninfected M2 macrophages
reflecting their anti-inflammatory function. From these observations it is suggested that
the series of events occurring at the initial site of HSV-1 infection lead to the production
of the M1 pro-inflammatory macrophage subtype following IFN-γ production by NK
cells and γ/δ T cells (Cunningham et al., 2006; Mikloska et al., 1998). Resistance to
SOCS1 manipulation through HSV-1 infection is necessary in maintaining an effective
immune response against the virus.
Together our data show the importance of microenvironment signals during
HSV-1 infections. During infection, large amounts of IFN-γ, produced by NK cells and
γ/δ T cells, would be present causing polarization to the M1 phenotype, which is
necessary to control virus replication. In this study, introducing HSV-1 to M1 cultures
caused a decrease in CD14 and CD86 expression; but significant increase in SOCS3
expression. However, SOCS1 plays the greater role in inhibiting IFN-γ signaling and
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dampening the inflammatory response. M2 macrophages showed a significant decrease in
total CD14-CD86 expression following virus treatment, while SOCS expression levels
remained relatively unchanged. The biggest observable change came in virus-infected
control cells, which exhibited significant up regulation of SOCS1. These data suggest that
microenvironment signals inhibit the ability of HSV-1 to up regulate SOCS1 and
decrease the effectiveness of macrophages to control virus replication (Fig. 30).
In future studies it would be beneficial to study the secretory products of the M1
and M2 phenotypes. This would provide additional markers for identification. Also, when
studying cell viability, it appears necessary to collect the supernatant and add both antiTNF-α and anti-IFN-γ neutralizing antibodies to inhibit production of TNF-α once the
supernatant is reintroduced back to culture, therefore, additional work needs to be
completed on the decrease in cell viability following M1 treatment. Also, the
development of a system that would allow for quick identification of the two phenotypes
would be vastly beneficial. This could be accomplished by inserting the iNOS promoter
(M1 marker) and the Arginase I promoter (M2 marker) into a plasmid engineered to
produce either GFP or RFP when the promoter is activated. This would allow for timelapse studies to be completed, which could verify how quickly polarization can occur,
and how long polarization can be maintained.
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Figure 1. J774A.1 macrophages treated with: Top, IFN-γ and LPS Middle, IL-4 Bottom,
or untreated. Right, Texas-Red Phalloidin X stain showing actin arrangement of each
macrophage experimental group. M1 macrophages appeared flattened, were irregularly
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shaped, and contained visible intracellular vacuoles. M2 macrophages exhibited an
elongated morphology that was similar to the morphology of control cells.
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Figure 2. J774A.1 macrophages treated with IFN-γ and LPS for 24 hours and: A, stained
with anti-CD14 FITC-conjugated antibodies B, stained with anti-CD86 Brilliant Violet
421-conjugated antibodies C, stained with Texas-Red Phalloidin X D, and CD14, CD86,
and Phalloidin merged image. M1 macrophages showed an increase in CD86 expression
when compared to control cells. (Images captured at 400X magnification, scale bar =
50µm)
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Figure 3. J774A.1 macrophages treated with IL-4 for 24 hours and: A, stained with antiCD14 FITC-conjugated antibodies B, stained with anti-CD86 Brilliant Violet 421conjugated antibodies C, stained with Texas-Red Phalloidin X D, and CD14, CD86, and
Phalloidin merged image. M2 macrophages showed a decrease in CD86 expression when
compared to control cells. (Images captured at 400X magnification, scale bar = 50µm)
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Figure 4. J774A.1 macrophages untreated for 24 hours and: A, stained with anti-CD14
FITC-conjugated antibodies B, stained with anti-CD86 Brilliant Violet 421-conjugated
antibodies C, stained with Texas-Red Phalloidin X D, CD14, CD86, and Phalloidin
merged image. (Images captured at 400X magnification, scale bar = 50µm)
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Figure 5. Flow cytometry analysis of CD14-CD86 expression levels in M1, M2, and
control macrophages. Negative isotype control CD14 and CD86 antibodies were used to
set quadrants. M1 macrophages had a significant increase (41.2%) in the number of
CD14+-CD86+ cells when compared to control cells, while M2 macrophages had a
decrease (26.0%) in the number of CD14+-CD86+ cells, however, the decrease was
statistically insignificant.
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Figure 6. Percentage averages of CD14+-CD86+ cells. There was an increase (41.2%, pvalue=0.024) in the number of CD14+-CD86+ M1 macrophages when compared to the
control cells. There was a decrease (26.9%, p-value=0.100) in the number of CD14+CD86+ M2 macrophages when compared to control cells, however, the results were
statistically insignificant. (*=p-value<0.05)
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Figure 7. Percentage of viable cells following polarization treatment. M1 macrophages
showed a decrease (31.0%, p-value<0.001) in cell viability following IFN-γ/LPS
treatment for 24 hours. M2 macrophages showed a slight decrease (9.0%, p-value=0.004)
in cell viability following treatment with IL-4 for 24 hours. (*=p-value<0.05, **=pvalue<0.001)
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Figure 8. SOCS1 and SOCS3 expression levels in M1 macrophages: stained with A, antiSOCS1 antibodies B, anti-SOCS3 antibodies C, anti-SOCS1 antibodies/Phalloidin
merged image D, and anti-SOCS3 antibodies/Phalloidin merged image. M1 macrophages
expressed higher levels of SOCS1 when compared to SOCS3. (Images captured at 400X
magnification, scale bar = 50µm)
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Figure 9. SOCS1 and SOCS3 expression of M2 macrophages: stained with A, antiSOCS1 antibodies B, anti-SOCS3 antibodies C, anti-SOCS1 antibodies/Phalloidin
merged image D, and anti-SOCS3 antibodies/Phalloidin merged image. M2 macrophages
expressed higher levels of SOCS3 when compared to SOCS1. (Images captured at 400X
magnification, scale bar = 50µm)
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Figure 10. SOCS1 and SOCS3 expression of control macrophages: stained with A, antiSOCS1 antibodies B, anti-SOCS3 antibodies C, anti-SOCS1 antibodies/Phalloidin
merged image D, and anti-SOCS3 antibodies/Phalloidin merge. Control macrophages
expressed higher levels of SOCS3 when compared to SOCS1. (Images captured at 400X
magnification, scale bar = 50µm)
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Figure 11. Flow cytometry analysis of: Left, SOCS1 Right, and SOCS3 expression
levels in M1 macrophages at 24 hours. M1 macrophages expressed higher levels of
SOCS1 when compared to SOCS3 with a SOCS1/SOCS3 ratio of 6.1:1.
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Figure 12. Flow cytometry analysis of: Left, SOCS1 Right, and SOCS3 expression
levels in M2 macrophages at 24 hours. M2 macrophages expressed higher levels of
SOCS3 when compared to SOCS1 with a SOCS1/SOCS3 ratio of 1:2.2.
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Figure 13. Flow cytometry analysis of: Left, SOCS1 Right, and SOCS3 expression
levels in control macrophages at 24 hours. Control macrophages expressed higher levels
of SOCS3 when compared to SOCS1 with a SOCS1/SOCS3 ratio of 1:1.9.
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Figure 14. SOCS1-SOCS3 ratio for M1, M2, and control macrophages. Control
macrophages SOCS expression levels were similar to M2 macrophage SOCS expression
levels, with both expressing higher levels of SOCS3 when compared to SOCS1. M1
macrophages expressed higher amounts of SOCS1 when compared to SOCS3.
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Figure 15. Virus-infected (0.1 MOI) J774A.1 macrophages treated with: Top, IFN-γ and
LPS Middle, IL-4 Bottom, or uninfected. Right, Texas-Red Phalloidin X stain showing
actin arrangement of each macrophage experimental group. Following virus challenge,
cells in all three experimental groups exhibited a rounded morphology.
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Figure 16. Virus-infected (0.1 MOI) J774A.1 macrophages treated with IFN-γ and LPS
for 24 hours and: A, stained with anti-CD14 FITC-conjugated antibodies B, stained with
anti-CD86 Brilliant Violet 421-conjugated antibodies C, stained with Texas-Red
Phalloidin X D, and CD14, CD86, and Phalloidin merged image. M1 macrophages
showed an increase in CD86 expression when compared to virus-infected control cells.
(Images captured at 400X magnification, scale bar = 50µm)
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Figure 17. Virus-infected (0.1 MOI) J774A.1 macrophages treated with IL-4 for 24
hours and: A, stained with anti-CD14 FITC-conjugated antibodies B, stained with antiCD86 Brilliant Violet 421-conjugated antibodies C, stained with Texas-Red Phalloidin X
D, and CD14, CD86, and Phalloidin merged image. There was no observable difference
in CD86 expression when compared to virus-infected control cells. (Images captured at
400X magnification, scale bar = 50µm)
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Figure 18. J774A.1 macrophages infected with 0.1 MOI of HSV-1 for 24 hours and: A,
stained with anti-CD14 FITC-conjugated antibodies B, stained with anti-CD86 Brilliant
Violet 421-conjugated antibodies C, stained with Texas-Red Phalloidin X D, and CD14,
CD86, and Phalloidin merged image. (Images captured at 400X magnification, scale bar
= 50µm)
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Figure 19. Flow cytometry analysis of CD14-CD86 expression in virus-infected (0.1
MOI) M1, M2, and control macrophages. Negative isotype control CD14 and CD86
antibodies were used to set quadrants. There was a 29.6% increase in CD14-CD86
ecpression in virus-infected M1 macrophages when compared to virus-infected control
cells, and an 11.4% decrease in CD14-CD86 expression in virus-infected M2
macrophages, however, the results were statistically insignificant.
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Figure 20. Average percentages of CD14+-CD86+ cells in virus-infected M1, M2, and
control macrophages. There was an increase (29.6%, p-value=0.055) in the number of
CD14+-CD86+ virus-infected M1 macrophages when compared to virus-infected control
cells. There was a decrease (11.4%, p-value=0.158) in the number of CD14+-CD86+
virus-infected M2 macrophages when compared to virus-infected control cells, however,
the results were statistically insignificant.
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Figure 21. Average percentages of CD14+-CD86+ cells for uninfected and virus-infected
M1, M2, and control macrophages. There was a decrease (39.4%, p-value=0.001) in the
number of CD14+-CD86+ virus-infected M1 macrophages when compared to uninfected
M1 macrophages. There was a decrease (13.2%, p-value=0.039) in the number of CD14+CD86+ virus-infected M2 macrophages when compared to uninfected M2 macrophages.
Additionally, virus-infected control cells experienced a decrease in the number of CD14+CD86+ cells when compared to control cells not challenged with virus. These results
suggest that HSV-1 infection decreases CD14 and CD86 expression in M1, M2, and
control macrophages. (*=p-value<0.05)
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Figure 22. Percentage of virus-infected viable cells following polarization treatment.
Virus-infected M1 macrophages showed a decrease (31.0%, p-value=0.003) in cell
viability following IFN-γ/LPS treatment for 24 hours. M2 macrophages cell viability
values were statistically insignificant from virus-infected control cells. (*=p-value<0.05)
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Figure 23. SOCS1 and SOCS3 expression levels in virus-infected M1 macrophages:
stained with A, anti-SOCS1 antibodies B, anti-SOCS3 antibodies C, anti-SOCS1
antibodies/Phalloidin merged image D, and anti-SOCS3 antibodies/Phalloidin merged
image. Virus-infected M1 macrophages expressed comparable levels of SOCS1 when
compared to SOCS3. (Images captured at 400X magnification, scale bar = 50µm)
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Figure 24. SOCS1 and SOCS3 expression levels in virus-infected M2 macrophages:
stained with A, anti-SOCS1 antibodies B, anti-SOCS3 antibodies C, anti-SOCS1
antibodies/Phalloidin merged image D, and anti-SOCS3 antibodies/Phalloidin merged
image. Virus-infected M2 macrophages expressed higher levels of SOCS3 when
compared to SOCS1. (Images captured at 400X magnification, scale bar = 50µm)
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Figure 25. SOCS1 and SOCS3 expression levels in virus-infected control macrophages:
stained with A, anti-SOCS1 antibodies B, anti-SOCS3 antibodies C, anti-SOCS1
antibodies/Phalloidin merged image D, and anti-SOCS3 antibodies/Phalloidin merged
image. Virus-infected control macrophages expressed higher levels of SOCS1 when
compared to SOCS3. (Images captured at 400X magnification, scale bar = 50µm)
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Figure 26. Flow cytometry analysis of: Left, SOCS1 Right, and SOCS3 expression
levels in virus-infected M1 macrophages at 24 hours. Virus-infected M1 macrophages
expressed comparable levels of SOCS1 when compared to SOCS3 with a SOCS1/SOCS3
ratio of 1:1.1.
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Figure 27. Flow cytometry analysis of: Left, SOCS1 Right, and SOCS3 expression
levels in virus-infected M2 macrophages at 24 hours. Virus-infected M2 macrophages
expressed higher levels of SOCS3 when compared to SOCS1 with a SOCS1/SOCS3 ratio
of 1:1.8.
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Figure 28. Flow cytometry analysis of: Left, SOCS1 Right, and SOCS3 expression
levels in virus-infected control macrophages at 24 hours. Virus-infected control
macrophages expressed higher levels of SOCS1 when compared to SOCS3 with a
SOCS1/SOCS3 ratio of 3.8:1.
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Figure 29. SOCS1-SOCS3 ratio for virus-infected M1, M2, and control macrophages.
Virus-infected control macrophages expressed higher levels of SOCS1 when compared to
SOCS3. Virus-infected M1 macrophages expressed comparable levels of SOCS1 and
SOCS3; while virus-infected M2 macrophages expressed higher levels of SOCS3 when
compared to SOCS1.
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Figure 30. Diagram outlining the effects of HSV-1 on polarized J774A.1 macrophages.
Viral challenge led morphological changes in M1, M2, and control macrophages.
Additionally, HSV-1 infection decreased the ability of all cell types to express CD14 and
CD86. In control cells, virus challenge leads to increased expression of SOCS1 when
compared to uninfected control cells. M1 macrophages expressed higher levels of SOCS3
following virus infection.
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SOCS1

SOCS3

M1 No Virus

34.7%

5.7%

M1 Virus

33.6%

36.1%

M2 No Virus

37.3%

81.5%

M2 Virus

47.6%

85.4%

Control No Virus

30.5%

57.7%

Control Virus

83.7%

22.1%

Table 1. Averages of SOCS expression levels in M1, M2, and control Macrophages
before and following virus treatment. SOCS3 was increased in M1 macrophages
following challenge with virus. SOCS expression levels remained relatively unchanged in
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the M2 phenotype, and in virus-infected control cells, SOCS1 was significantly
increased.
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